Ariana Pelosci, associate editor for CancerNetwork®, has been with the team since June 2021. She specializes both in web and print, and runs the social media for CancerNetwork®.
She is a graduate of the University of Delaware, where she studied Media Communications and minored in journalism and marketing. At heart, she is a Jersey girl, and you can always find her down the shore during her free time.
Ariana loves to read, specifically historical or contemporary fiction. Follow Ariana on Twitter @APelosci or email her at email@example.com.
BXCL701/Pembrolizumab Yields Durable Responses in Prostate Cancer SubtypeMarch 10th 2023
All patients with platinum-resistant, small-cell neuroendocrine prostate cancer who responded to treatment with BXCL701 plus pembrolizumab were microsatellite stable and/or tumor mutational burden–low with a low probability of response to pembrolizumab.
FDA ODAC Votes in Favor of Polatuzumab Vedotin in Previously Untreated DLBCLMarch 10th 2023
Polatuzumab vedotin-piiq plus R-CHP was found to produce clinical efficacy in phase 3 POLARIX trial in patients with previously untreated diffuse large B-cell lymphoma, leading to an 11-to-2 vote from the FDA’s Oncologic Drug Advisory Committee.
FDA Approves Pegfilgrastim Biosimilar to Mitigate Febrile Neutropenia From ChemoMarch 6th 2023
A prefilled autoinjector presentation of pegfilgrastim-cbqv, a pegfilgrastim biosimilar, has been approved by the FDA for patients with cancer undergoing chemotherapy who may experience febrile neutropenia.
TFS Improves With Nivolumab, Salvage Nivolumab in Advanced Renal Cell CarcinomaFebruary 21st 2023
Results from cohort A of the HCRN GU16-260 trial showed treatment-free survival was enhanced in patients with advanced renal cell carcinoma who received nivolumab monotherapy plus salvage nivolumab and ipilimumab maintenance.
Ponatinib Combo Demonstrates Superiority Vs Imatinib in Ph+ Leukemia SubtypeFebruary 16th 2023
An expert from the University of Texas MD Anderson Cancer Center says that ponatinib plus reduced-intensity chemotherapy may be a new standard of care for frontline Philadelphia chromosome–positive acute lymphoblastic leukemia.
ODAC Votes 8-5 in Favor of Dostarlimab Trial in Advanced Rectal CancerFebruary 9th 2023
In a meeting with the FDA’s Oncologic Drugs Advisory Committee experts discussed findings that have read out with regard to dostarlimab for patients with mismatch repair deficiency/microsatellite instability–high locally advanced rectal cancer.
FDA Approves Sacituzumab Govitecan-hziy in Pre-Treated HR+/HER2– Advanced Breast CancerFebruary 3rd 2023
Patients with pre-treated, unresectable locally advanced or metastatic hormone receptor-positive, HER2-negative breast cancer can now receive treatment with sacituzumab govitecan following approval from the FDA.
Updated Capecitabine Approval Ignites ‘Broad Impact’ in Cancer Under New FDA ProgramJanuary 23rd 2023
Under a new FDA initiative, the agency recently updated a decades’ old approval of the chemotherapy capecitabine. This move, according to an expert, will springboard further change in the treatment of cancer.
University of Pennsylvania Experts Discuss Treatment Options in Transplant-Eligible and -Ineligible Newly Diagnosed Multiple MyelomaDecember 24th 2022
Experts present patient cases of those with transplant-eligible or ineligible multiple myeloma and discuss the current standard of care treatment, and how to apply it to their patients.
Lenalidomide Plus Rituximab Improved PFS in 5-Year Follow-Up for R/R Indolent Non-Hodgkin LymphomaDecember 10th 2022
The 5-year follow-up of the phase 3 AUGMENT trial produced enhanced progression-free survival when lenalidomide plus rituximab was used to treat patients with relapsed/refractory indolent non-Hodgkin lymphoma.
Capivasertib Plus Fulvestrant Yields PFS Improvement in HR+/HER2– Breast CancerDecember 8th 2022
Results from the phase 3 CAPItello-291 trial indicated that the combination of capivasertib plus fulvestrant produced improved progression-free survival in patients who have hormone-receptor–positive/HER2-negative advanced breast cancer.
Vaccine-Chemoradiotherapy Combo Produces 100% Clinical Response in Advanced Cervical CancerNovember 15th 2022
Results from the ongoing phase 2 IMMUNOCERV trial showed that treatment with the investigational drug PDS0101 — a vaccine — combined with chemotherapy and radiation induced a 100% clinical response in a small group of patients with stage IB3 to IVA cervical cancer.
FDA Grants Accelerated Approval to Mirvetuximab Soravtansine for Subset of Platinum-Resistant Ovarian CancerNovember 14th 2022
The FDA has granted mirvetuximab soravtansine-gynx an accelerated approval for the treatment of patients with folate receptor-α-positive platinum-resistant ovarian cancer based on results from the phase 3 SORAYA study.